Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.87

€3.87

1.710%
0.065
1.710%
€8.50

€8.50

 
Latest predictions
€8.00
18.01.21
buy
-
28.10.20
€5.00
16.03.20
buy
-
11.01.20
buy
€12.00
20.09.19
buy
€9.00
15.07.19
buy
Your prediction

Medigene AG Stock

There is an upward development for Medigene AG compared to yesterday, with an increase of €0.065 (1.710%).
Currently there is a rather positive sentiment for Medigene AG with 5 Buy predictions and 1 Sell predictions.
With a target price of €8.00 there is potential for a 106.986% increase which would mean more than doubling the current price of €3.87 for Medigene AG.
Our community identified positive and negative aspects for Medigene AG stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Medigene AG stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of Medigene AG in the next few years

Pros
1
Could be worthwhile Investment >10% per year
1
Innovative
Cons
1
Higher risks for its business
1
Dependend from some customers or products

Performance of Medigene AG vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Medigene AG 1.710% -2.564% -13.242% -19.355% 7.496% -77.778% -51.752%
Biofrontera AG -1.920% -3.512% -19.444% -41.935% -12.709% -51.667% 19.287%
Formycon AG -3.190% -6.006% 1.623% 151.406% 18.113% 101.610% 174.899%
B.R.A.I.N. Biotechnology Research and Information Network AG 3.000% -17.129% -1.591% -6.580% -4.415% -63.070% -12.737%

Comments

Buy Medigene AG

Buy Medigene AG

Sell Medigene AG

Other discussions about Medigene AG Stock

Trading Medigene AG

Trading Medigene AG

New thread Forum

News

Medigene AG: Further encouraging results from long-term follow-up of AML patients in DC vaccine trial

Business news for the stock market

 

Planegg/Martinsried (08.02.2021/16:00) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the

Focus on solid tumors - Discontinuation of MDG1021 development program

Conference call today, 3.00 pm CET (9.00 am ET)

 

Planegg/Martinsried (28.01.2021) - 28 January 2021. The Executive Management of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical

Medigene AG: Medigene expands patent protection of its technologies in key markets, the USA and Europe

Planegg/Martinsried (13.01.2021) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, was